JP6775488B2 - 前立腺がんの診断に関連する組成物および方法 - Google Patents

前立腺がんの診断に関連する組成物および方法 Download PDF

Info

Publication number
JP6775488B2
JP6775488B2 JP2017502945A JP2017502945A JP6775488B2 JP 6775488 B2 JP6775488 B2 JP 6775488B2 JP 2017502945 A JP2017502945 A JP 2017502945A JP 2017502945 A JP2017502945 A JP 2017502945A JP 6775488 B2 JP6775488 B2 JP 6775488B2
Authority
JP
Japan
Prior art keywords
subject
prostate cancer
probability
tpsa
prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017502945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515127A (ja
Inventor
デイビッド・スタインミラー
ビンセント・リンダー
キム・ペッテルソン
ティモ・ロヴグリン
ハンス・リルヤ
ピーター・ティ・スカーディノ
アンドリュー・ジェイ・ビッカーズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OPKO Diagnostics LLC
Original Assignee
OPKO Diagnostics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OPKO Diagnostics LLC filed Critical OPKO Diagnostics LLC
Publication of JP2017515127A publication Critical patent/JP2017515127A/ja
Application granted granted Critical
Publication of JP6775488B2 publication Critical patent/JP6775488B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Evolutionary Biology (AREA)
  • Primary Health Care (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Software Systems (AREA)
  • Evolutionary Computation (AREA)
JP2017502945A 2014-03-28 2015-03-27 前立腺がんの診断に関連する組成物および方法 Active JP6775488B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461972099P 2014-03-28 2014-03-28
US61/972,099 2014-03-28
PCT/US2015/023096 WO2015148979A1 (en) 2014-03-28 2015-03-27 Compositons and methods related to diagnosis of prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020169099A Division JP7256781B2 (ja) 2014-03-28 2020-10-06 前立腺がんの診断に関連する組成物および方法

Publications (2)

Publication Number Publication Date
JP2017515127A JP2017515127A (ja) 2017-06-08
JP6775488B2 true JP6775488B2 (ja) 2020-10-28

Family

ID=54196462

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017502945A Active JP6775488B2 (ja) 2014-03-28 2015-03-27 前立腺がんの診断に関連する組成物および方法
JP2020169099A Active JP7256781B2 (ja) 2014-03-28 2020-10-06 前立腺がんの診断に関連する組成物および方法
JP2022172333A Active JP7506131B2 (ja) 2014-03-28 2022-10-27 前立腺がんの診断に関連する組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020169099A Active JP7256781B2 (ja) 2014-03-28 2020-10-06 前立腺がんの診断に関連する組成物および方法
JP2022172333A Active JP7506131B2 (ja) 2014-03-28 2022-10-27 前立腺がんの診断に関連する組成物および方法

Country Status (24)

Country Link
US (2) US11761962B2 (enExample)
EP (2) EP3123381B1 (enExample)
JP (3) JP6775488B2 (enExample)
KR (1) KR102505543B1 (enExample)
CN (2) CN106663149A (enExample)
AR (1) AR099883A1 (enExample)
AU (1) AU2015237270B2 (enExample)
CA (1) CA2944001C (enExample)
CL (1) CL2016002419A1 (enExample)
DE (1) DE202015009668U1 (enExample)
DK (1) DK3123381T3 (enExample)
EA (1) EA201691952A1 (enExample)
ES (1) ES2964706T3 (enExample)
FI (1) FI3123381T3 (enExample)
HU (1) HUE065029T2 (enExample)
IL (2) IL247981B (enExample)
MX (2) MX392384B (enExample)
MY (1) MY192513A (enExample)
PE (1) PE20170298A1 (enExample)
PL (1) PL3123381T3 (enExample)
PT (1) PT3123381T (enExample)
SG (2) SG10201808585TA (enExample)
TW (1) TWI687688B (enExample)
WO (1) WO2015148979A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2152417B1 (en) 2007-05-04 2018-07-11 Opko Diagnostics, LLC Device and method for analyses in microfluidic systems
EP2391451B1 (en) 2009-02-02 2018-09-12 Opko Diagnostics, LLC Structures for controlling light interaction with microfluidic devices
MX362555B (es) 2012-03-05 2019-01-24 Oy Arctic Partners Ab Metodos y aparatos para predecir riesgo de cancer de prostata y volumen de glandula prostatica.
US12326453B2 (en) * 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
PT3253800T (pt) 2015-03-27 2021-04-28 Opko Diagnostics Llc Padrões de antigénio da próstata e suas utilizações
CA2998818A1 (en) * 2015-10-05 2017-04-13 Fredax Ab Humanized anti psa (5a10) antibodies
US10852310B2 (en) 2015-12-11 2020-12-01 Opko Diagnostics, Llc Fluidic systems involving incubation of samples and/or reagents
EP3397387B1 (en) 2015-12-29 2021-03-24 Opko Diagnostics, LLC Fluid collection device and related methods
JP2020507838A (ja) * 2017-01-08 2020-03-12 ザ ヘンリー エム．ジャクソン ファンデーション フォー ザ アドバンスメント オブ ミリタリー メディシン，インコーポレーテッド 対象特有の肺炎転記を予測するための教師付き学習を使用するためのシステムおよび方法
KR102052398B1 (ko) 2018-04-18 2019-12-05 (주)유로테크 전립선암 진단용 바이오마커 및 이의 용도
WO2020205204A1 (en) 2019-04-03 2020-10-08 Opko Diagnostics, Llc Methods for the detection of prostate cancer
ES3040560T3 (en) * 2019-10-11 2025-11-03 C The Signs Ltd Diagnostic tool
KR102730255B1 (ko) * 2022-08-12 2024-11-15 (주)맥시온 암 진단용 다중 바이오마커 및 이의 용도
CN118629514B (zh) * 2024-08-08 2024-10-29 上海橙帆医药有限公司 序列免疫原性预测方法、装置、电子设备及存储介质

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
US5516639A (en) 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
EP0635575A1 (en) 1993-07-22 1995-01-25 Wallac Oy Monoclonal antibodies against epitopes found in free but not in alpha-1-antichmotrypsin complexed prostate specific antigen
ATE263962T1 (de) 1993-10-28 2004-04-15 I Stat Corp Vorrichtung zur abnahme und einleitung von flüssigkeitsproben
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5585069A (en) 1994-11-10 1996-12-17 David Sarnoff Research Center, Inc. Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis
US5614372A (en) 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
KR19990036069A (ko) 1995-08-03 1999-05-25 이.에이치. 리링크 진단 장치
US6143509A (en) 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
WO1997039351A1 (en) 1996-04-12 1997-10-23 Carter Herbert B Novel methods for the prediction and early detection of prostatic adenocarcinoma
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
US5945289A (en) 1996-12-20 1999-08-31 Lehrer; Steven Method for detecting prostate cancer by apolipoprotein E (Apo-E) genotyping
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
SE9704934D0 (sv) 1997-12-30 1997-12-30 Pharmacia & Upjohn Diag Ab Analysförfarande med tillsättning i två eller flera positioner
FI980488A7 (fi) 1998-03-04 1999-09-05 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
FR2780791B1 (fr) 1998-07-03 2000-09-01 Bio Merieux Methode de depistage ou de diagnostic d'un adenocarcinome ou d'une pathologie benigne de la prostate et procede de mise en oeuvre
US6551778B1 (en) 1999-01-28 2003-04-22 Gen-Probe Incorporated Nucleic acid sequences for detecting genetic markers for cancer in a biological sample
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US7211397B2 (en) 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
US6136549A (en) 1999-10-15 2000-10-24 Feistel; Christopher C. systems and methods for performing magnetic chromatography assays
FI20002127A0 (fi) 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
AU2001297014A1 (en) 2000-10-10 2002-04-22 Aviva Biosciences Corporation An integrated biochip system for sample preparation and analysis
CA2428011A1 (en) 2000-11-20 2002-06-13 Eastern Virginia Medical School Methods and devices for the quantitative detection of prostate specific membrane antigen and other prostatic markers
AU2002362447A1 (en) 2001-10-03 2003-04-14 University Of Rochester Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
US7258837B2 (en) 2001-12-05 2007-08-21 University Of Washington Microfluidic device and surface decoration process for solid phase affinity binding assays
US20030235816A1 (en) 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
US20050272052A1 (en) 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
JPWO2003100425A1 (ja) 2002-05-28 2005-11-04 株式会社常光 免疫学的クロマトグラフ法の試験紙片の読み取り定量装置
DK1540010T3 (da) 2002-08-06 2010-07-26 Univ Johns Hopkins Anvendelse af biomarkører til påvisning af ovariecancer
US20040115794A1 (en) 2002-12-12 2004-06-17 Affymetrix, Inc. Methods for detecting transcriptional factor binding sites
CA2513780C (en) 2003-02-07 2014-12-30 Diagnocure Inc. Method to detect prostate cancer from a urine sample
US7461048B2 (en) 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US20060269971A1 (en) 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer
US20050118061A1 (en) 2003-11-28 2005-06-02 Sysmex Corporation Analyzer, assay cartridge and analyzing method
EP1691924B1 (en) 2003-12-10 2016-09-14 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin A modular biochip assembly
CA2564609C (en) 2003-12-31 2014-02-11 President And Fellows Of Harvard College Assay device and method
US8030057B2 (en) 2004-01-26 2011-10-04 President And Fellows Of Harvard College Fluid delivery system and method
EP1776181B1 (en) 2004-01-26 2013-09-11 The President and Fellows of Harvard College Fluid delivery system and method
TW200538734A (en) 2004-03-12 2005-12-01 Aureon Biosciences Corp Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
EP1747466A2 (en) 2004-05-11 2007-01-31 Baylor College Of Medicine Method to predict prostate cancer
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
WO2006022895A2 (en) 2004-08-02 2006-03-02 Children's Medical Center Corporation Platelet biomarkers for cancer
AU2005287074A1 (en) 2004-09-17 2006-03-30 Ciphergen Biosystems, Inc. Biomarkers for breast cancer
US8663600B2 (en) 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
WO2006122311A2 (en) 2005-05-11 2006-11-16 The Trustees Of The University Of Pennsylvania Microfluidic chip
US20070065954A1 (en) 2005-09-15 2007-03-22 Minoru Taya Surface plasmon resonance biosensor system for detection of antigens and method for determining the presence of antigens
AU2007231487B2 (en) 2006-03-24 2014-01-09 Phenomenome Discoveries Inc. Biomarkers useful for diagnosing prostate cancer, and methods thereof
AU2007271232A1 (en) 2006-07-03 2008-01-10 Exonhit Therapeutics Sa Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
CN1973778A (zh) 2006-12-08 2007-06-06 南京大学 胃癌术后严重并发症风险度的预测方法
US9182400B2 (en) 2006-12-22 2015-11-10 Phadia Ab Prostate kallikrein allergen
EP2152417B1 (en) 2007-05-04 2018-07-11 Opko Diagnostics, LLC Device and method for analyses in microfluidic systems
CA2686954A1 (en) * 2007-05-08 2008-11-20 Picobella Llc Methods for diagnosing and treating prostate and lung cancer
CN101329343A (zh) 2007-06-19 2008-12-24 天津迪爱盟生物技术有限公司 新一代早期诊断前列腺癌试剂盒及其制备方法和检测方法
WO2009029550A2 (en) 2007-08-24 2009-03-05 Singulex, Inc. Highly sensitive system and methods for analysis of prostate specific antigen (psa)
CN101377500A (zh) 2007-08-31 2009-03-04 北京科美东雅生物技术有限公司 游离前列腺特异性抗原化学发光免疫分析测定试剂盒及其制备方法
JP5272011B2 (ja) 2007-10-22 2013-08-28 セントビンセンツ ホスピタル シドニー リミテッド 予後判定の方法
WO2009085196A1 (en) 2007-12-21 2009-07-09 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
JP5028697B2 (ja) 2008-02-18 2012-09-19 富士フイルム株式会社 吸引シリンジ及び内視鏡用吸引シリンジ
CA2724433A1 (en) 2008-05-14 2009-11-19 Eth Zuerich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
FR2934698B1 (fr) 2008-08-01 2011-11-18 Commissariat Energie Atomique Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede.
US8386187B2 (en) 2008-10-20 2013-02-26 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same
CA2745961A1 (en) 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
WO2010080115A2 (en) 2008-12-18 2010-07-15 Claros Diagnostics, Inc. Improved reagent storage in microfluidic systems and related articles and methods
US20100168621A1 (en) 2008-12-23 2010-07-01 Neville Thomas B Methods and systems for prostate health monitoring
US20120022793A1 (en) 2009-01-19 2012-01-26 Miraculins, Inc. Biomarkers for the diagnosis of prostate cancer in a non-hypertensive population
EP2391451B1 (en) 2009-02-02 2018-09-12 Opko Diagnostics, LLC Structures for controlling light interaction with microfluidic devices
JP2010243406A (ja) 2009-04-08 2010-10-28 F Hoffmann La Roche Ag Ａｆｐおよびｐｉｖｋａ−ｉｉの測定値を特徴値とした識別関数を利用する、肝臓癌および慢性肝疾患の病態進行度の検出方法
SG175832A1 (en) 2009-05-01 2011-12-29 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
CN102483416A (zh) 2009-06-04 2012-05-30 梅坦诺米克斯保健有限公司 诊断前列腺癌的工具和方法
WO2011027308A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2011027310A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
KR101141190B1 (ko) * 2009-10-19 2012-06-13 중앙대학교 산학협력단 전립선암에 대한 바이오마커 및 이를 이용한 전립선암 진단
BR112012022917A2 (pt) * 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
CA3016653C (en) 2010-04-16 2024-01-02 Opko Diagnostics, Llc Feedback control in microfluidic systems
WO2012029080A1 (en) 2010-08-30 2012-03-08 Decode Genetics Ehf Sequence variants associated with prostate specific antigen levels
BRPI1100857A2 (pt) 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
US9594086B2 (en) 2011-03-22 2017-03-14 The Johns Hopkins University Biomarkers for aggressive prostate cancer
WO2012170776A2 (en) 2011-06-09 2012-12-13 Quanterix Corporation Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
US9638706B2 (en) 2011-07-21 2017-05-02 Wako Pure Chemical Industries, Ltd. Standard solution for use in analysis of amino acid in plasma
LT2771037T (lt) 2011-10-28 2017-01-25 Fredax Ab Terapiniai agentai ir jų panaudojimas
WO2013106778A2 (en) 2012-01-13 2013-07-18 Iris International, Inc. Non-equilibrium two-site assays for linear, ultrasensitive analyte detection
MX362555B (es) 2012-03-05 2019-01-24 Oy Arctic Partners Ab Metodos y aparatos para predecir riesgo de cancer de prostata y volumen de glandula prostatica.
RU2014150777A (ru) * 2012-05-16 2016-07-10 Пхадиа Аб Способ индикации наличия или отсутствия рака предстательной железы
AU2013284448B2 (en) 2012-06-27 2019-04-18 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
CN102818892B (zh) 2012-08-16 2015-02-18 北京恩济和生物科技有限公司 一种前列腺特异性抗原检测试剂盒及其制备方法
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
ES2694409T3 (es) 2012-11-20 2018-12-20 Phadia Ab Método de pronóstico para individuos con cáncer de próstata
MY182773A (en) 2012-11-20 2021-02-05 Phadia Ab Method for indicating a presence or non-presence of aggressive prostate cancer
CN105980404B (zh) 2013-11-19 2021-01-12 弗雷达克斯有限责任公司 人源化抗激肽释放酶-2抗体
EP4220170A3 (en) 2014-03-11 2023-12-13 Phadia AB Method for detecting a solid tumor cancer
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
WO2016145331A1 (en) 2015-03-12 2016-09-15 Thermo Finnigan Llc Methods for data-dependent mass spectrometry of mixed biomolecular analytes
PT3253800T (pt) 2015-03-27 2021-04-28 Opko Diagnostics Llc Padrões de antigénio da próstata e suas utilizações
EP3247387A4 (en) 2015-04-29 2018-09-12 Opko Diagnostics, LLC Compositions and methods for active surveillance of prostate cancer
US20190072555A1 (en) 2017-08-14 2019-03-07 Opko Diagnostics, Llc Multiplex assays for evaluating prostate cancer status
WO2019221930A1 (en) 2018-05-16 2019-11-21 Opko Diagnostics, Llc Methods for detecting prostate cancer pathology associated with adverse outcomes

Also Published As

Publication number Publication date
PL3123381T3 (pl) 2024-02-26
MX2022002365A (es) 2022-04-06
IL280039A (en) 2021-03-01
AU2015237270B2 (en) 2021-09-09
AU2015237270A1 (en) 2016-10-20
CA2944001A1 (en) 2015-10-01
MX2016012667A (es) 2017-01-09
IL280039B (en) 2021-12-01
MX392384B (es) 2025-03-24
TW201621320A (zh) 2016-06-16
JP7506131B2 (ja) 2024-06-25
AR099883A1 (es) 2016-08-24
CN106663149A (zh) 2017-05-10
SG11201608035UA (en) 2016-10-28
JP7256781B2 (ja) 2023-04-12
IL247981A0 (en) 2016-11-30
HUE065029T2 (hu) 2024-04-28
EP3123381A4 (en) 2018-02-21
TWI687688B (zh) 2020-03-11
DE202015009668U1 (de) 2019-01-21
EP3299977A1 (en) 2018-03-28
WO2015148979A8 (en) 2016-01-07
BR112016022407A2 (pt) 2017-12-12
FI3123381T3 (fi) 2023-11-27
KR102505543B1 (ko) 2023-03-02
EA201691952A1 (ru) 2017-05-31
WO2015148979A1 (en) 2015-10-01
US11761962B2 (en) 2023-09-19
IL247981B (en) 2021-02-28
PE20170298A1 (es) 2017-04-18
CN114740202A (zh) 2022-07-12
JP2023017841A (ja) 2023-02-07
CA2944001C (en) 2023-08-15
SG10201808585TA (en) 2018-11-29
ES2964706T3 (es) 2024-04-09
JP2017515127A (ja) 2017-06-08
US20230393137A1 (en) 2023-12-07
US20160025732A1 (en) 2016-01-28
DK3123381T3 (da) 2023-11-27
KR20170008729A (ko) 2017-01-24
PT3123381T (pt) 2023-12-22
JP2021009157A (ja) 2021-01-28
MY192513A (en) 2022-08-24
CL2016002419A1 (es) 2017-03-31
EP3123381A1 (en) 2017-02-01
EP3123381B1 (en) 2023-10-11

Similar Documents

Publication Publication Date Title
JP7506131B2 (ja) 前立腺がんの診断に関連する組成物および方法
JP6873916B2 (ja) 前立腺がんの積極的監視のための組成物および方法
US12326453B2 (en) Compositions and methods for active surveillance of prostate cancer
HK40078292A (en) Compositions and methods related to diagnosis of prostate cancer
EA041331B1 (ru) Композиции и методы, имеющие отношение к диагностике рака предстательной железы
HK1234177B (en) Compositions and methods related to diagnosis of prostate cancer
HK1234177A1 (en) Compositions and methods related to diagnosis of prostate cancer
BR112016022407B1 (pt) Métodos, computador, meio de armazenamento e sistemas relacionados ao diagnóstico do câncer de próstata
BR122024013391A2 (pt) Métodos, computador, meio de armazenamento e sistemas relacionados ao diagnóstico do câncer de próstata
BR122024013391B1 (pt) Métodos, computador, meio de armazenamento e sistemas relacionados ao diagnóstico do câncer de próstata

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180326

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200430

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200908

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201006

R150 Certificate of patent or registration of utility model

Ref document number: 6775488

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250